News
MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...
GlobalData on MSN8d
MSD receives FDA approval for Enflonsia to prevent RSVThe approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.
Medindia on MSN5d
FDA Approves ENFLONSIA to Shield Infants From RSVIn a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Zacks.com on MSN7d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in InfantsMRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback